1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tThe Motley Fool • 06/03/26
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside DownThe Motley Fool • 06/02/26
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?Zacks Investment Research • 05/29/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyThe Motley Fool • 05/19/26
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026PRNewsWire • 05/12/26
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026PRNewsWire • 05/05/26
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 04/29/26
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall StreetThe Motley Fool • 04/26/26
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 04/23/26